-
Mashup Score: 0Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors - 1 year(s) ago
PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space. METHODS This is a phase II open-label, single-center trial of localized unresectable or high-risk resectable MSI-H/dMMR tumors. Treatment is pembrolizumab 200 mg once every 3…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 - 1 year(s) ago
PURPOSE To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2. METHODS The study population included 15,104 prospectively followed women within the CARRIERS study treated with ipsilateral surgery for invasive breast cancer. The risk of CBC was estimated for PV carriers in each gene compared with women…
Source: Journal of Clinical OncologyCategories: General Medicine News, Latest HeadlinesTweet-
Researchers identify women with twice the risk of #cancer in both breasts @mayoclinic https://t.co/knkRgdepdC https://t.co/T29heXrwt0
-
-
Mashup Score: 5Immunotherapy in Localized Microsatellite Instability–High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care? - 1 year(s) ago
Section:The hallmark of mismatch repair deficiency is the inability to repair spontaneous mutations during DNA replication, resulting in high tumor mutational burden levels and altered DNA microsatellite sequences or microsatellite instability (MSI).1-3 Although initially this feature was identified as a preliminary screening test for hereditary cancer syndromes such as Lynch syndrome,4 mismatch…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
A measured but hopeful discussion of neoadjuvant immunotherapy approach strategies in MSI-high tumors, including colorectal cancers e.g. NICHE-2, by @KristenCiombor & @CathyEngMD in @JCO_ASCO #GI23 #crcsm https://t.co/Ukelg0f0iF
-
-
Mashup Score: 1Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial - 1 year(s) ago
PURPOSE Neoadjuvant chemotherapy (NAC) has potential advantages over standard postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation. METHODS Patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly allocated (2:1) to 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 postoperatively (NAC group) or 24 weeks postoperatively…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
🔥🔥🔥Thread by Dr. @JenSeligmann describing the just published FOxTROT trial! 👏🏼👏🏼 T3-4NxM0 colon cancer 3c neoadjuvant FOLFOX, compared with upfront surgery, ⬇️ risk of residual or recurrent disease within 2 years: 16.9% vs. 21.5%, P = .037. https://t.co/qR2LrpGieX https://t.co/ZsiLjmrFly
-
-
Mashup Score: 0Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial - 1 year(s) ago
PURPOSE Neoadjuvant chemotherapy (NAC) has potential advantages over standard postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation. METHODS Patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly allocated (2:1) to 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 postoperatively (NAC group) or 24 weeks postoperatively…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Preoperative Chemotherapy for Operable Colon #Cancer: Mature Results of an International Randomized Controlled Trial. https://t.co/lutohxTwy2 #GI23 #ColonCancer @ASCO @JCO_ASCO https://t.co/fSf8cItgCB
-
-
Mashup Score: 1
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@rajshekharucms @BijoyTelivala @bdermanmd @Amyloid_Planet @ManniMD1 @RahulBanerjeeMD @HadidiSamer @PlasmaCellPete @stuchman1 Also agree with omitting Cy - this is the RCT, comes up a lot on consults: https://t.co/aBllgI1cYM
-
-
Mashup Score: 7Gain of Function: Empathy for the Uncertain Patient With Cancer - 1 year(s) ago
The news came from the embassy. Chest x-rays were performed on all immigrants to screen for tuberculosis, and my father’s was markedly abnormal. A theologian with a masterful command of language, he would later write of “a tumorous excrescence of considerable magnitude and menace.”1(p403) But he described it to me, in terms comprehensible to his 8-year-old child, as a pineapple-sized cancer…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
"A hard-fought remission that ushers in constant fear is a Pyrrhic victory." Clinical responses do not banish all worries and, like occult malignancy itself, this dismay can lie below the surface while still greatly troubling our patients https://t.co/bXq5Bdg4lT https://t.co/vl7z5CuDk8
-
-
Mashup Score: 3
PURPOSE The regimens approved for the treatment of advanced head and neck squamous cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income countries because of their cost. In our previous study, metronomic chemotherapy improved survival in this setting. Retrospective data suggest that a low dose of nivolumab may be efficacious. Hence, we aimed to assess whether the…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Do our patients need more of much less immunotherapy? At least in India, Low-Dose Immunotherapy in Head and Neck Cancer can show improvement in OS: A Randomized Study https://t.co/EIPpU1Yxv0 @HosseinBorghaei
-
-
Mashup Score: 0
PURPOSE The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients (N = 465) with treatment-naive, advanced NSCLC without EGFR/ALK mutations were randomly assigned 2:1 to receive toripalimab 240 mg (n = 309) or placebo (n = 156) once every 3 weeks…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
ICYMI: Results of CHOICE-01 trial. An "advance" or "ho hum"? @utswcancer @UTSWHemeOnc @TimothyJBrownMD @timilpatel @guptaarjun90 @DrJedDowell @JVentoMD @rmelias2 @AKSHARMAMD18 https://t.co/vU9B4JwAC8
-
-
Mashup Score: 5
PURPOSE To provide guidance on the use of opioids to manage pain from cancer or cancer treatment in adults. METHODS A systematic review of the literature identified systematic reviews and randomized controlled trials of the efficacy and safety of opioid analgesics in people with cancer, approaches to opioid initiation and titration, and the prevention and management of opioid adverse events….
Source: Journal of Clinical OncologyCategories: Hematologists1, Latest HeadlinesTweet-
Use of opioids for adults with pain from cancer or cancer treatment: ASCO Guideline https://t.co/yujwGPEHYU https://t.co/bkUTgnro4d
-
👀 Check out what’s popular this week in #JCO: Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors ➡️ https://t.co/T0S40OF07w #ImmunoOnc https://t.co/riq1uOpJ6z